The impact of inter partes review on patent litigation
The America Invents Act (AIA) created a new post-grant review proceeding in the USPTO: the inter partes review or IPR. On 16 September, 2012, the USPTO stopped accepting petitions for inter partes re-examination and the IPR took its place.
IPR, like inter partes re-examination before it, allows the USPTO to reconsider the patentability of a patent. There are some key differences between an IPR and prior post-grant proceedings. For an IPR to be instituted, the USPTO must conclude there is ‘a reasonable likelihood that the petitioner would prevail’ in at least one of the claims; a more stringent standard than the old ‘significant new question of patentability’.
An IPR is conducted before the new USPTO Patent Trial and Appeal Board (PTAB), not an examiner, eliminating one layer of proceedings. Invalidity need only be proven by preponderance of the evidence, a lower standard than the federal court ‘clear and convincing’ standard…
If you are registered and logged in to the site, click on the link below to read the rest of the DLA Piper briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
Health Alert — Julia Clare v Australian Community Pharmacy Authority; Dr Reid v Medical Council of NSW; and more
DLA Piper has released the 22 December 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
The European Court of Justice (CJEU) has handed down a landmark judgment concerning the patentability of stem cells in Europe.
Analysis from The Lawyer
Regulators are ramping up the pressure in the aftermath of recession, leaving firms to compete for compliance and restructuring work
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.